Zhitong Finance App News, Weikang Pharmaceutical (300878.SZ) announced that on May 27, 2024, the company and relevant responsible personnel received the “Decision on Measures to Issue Warning Letters to Zhejiang Weikang Pharmaceutical Co., Ltd. and related responsible personnel” (“Warning Letter”) issued by the Zhejiang Regulatory Bureau (“Zhejiang Securities Regulatory Bureau”) of the China Securities Regulatory Commission.

According to reports, according to the “2023 Annual Report” disclosed by the company on April 29, 2024, the company's net profit attributable to shareholders of listed companies in 2023 was a loss of 8.0386 million yuan, and the company did not promptly disclose the 2023 performance forecast in accordance with regulations. The above acts of the company violate relevant regulations. Liu Zhongliang, chairman of the company, Kong Xiaoxia, general manager, Wang Jing, financial director, and Zhu Ting, secretary of the board of directors, are mainly responsible for these irregularities. According to regulations, the Zhejiang Securities Regulatory Bureau decided to take separate supervisory and administrative measures to issue warning letters against the company and the above personnel.